Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Update

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 774,700 shares, a drop of 79.0% from the October 31st total of 3,690,000 shares. Based on an average trading volume of 15,910,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 3.5% of the shares of the company are short sold.

Insider Activity at Tevogen Bio

In related news, insider Neal Flomenberg sold 1,078,600 shares of the firm’s stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $1.62, for a total transaction of $1,747,332.00. Following the sale, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. This trade represents a 20.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 56.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned approximately 0.13% of Tevogen Bio at the end of the most recent reporting period.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN traded down $0.06 during trading on Friday, reaching $1.31. 1,144,755 shares of the company’s stock traded hands, compared to its average volume of 4,936,248. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $21.09. The company has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $0.90.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.